Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.

de Bock CE, Demeyer S, Degryse S, Verbeke D, Sweron B, Gielen O, Vandepoel R, Vicente C, Vanden Bempt M, Dagklis A, Geerdens E, Bornschein S, Gijsbers R, Soulier J, Meijerink JP, Heinäniemi M, Teppo S, Bouvy-Liivrand M, Lohi O, Radaelli E, Cools J.

Cancer Discov. 2018 May;8(5):616-631. doi: 10.1158/2159-8290.CD-17-0583. Epub 2018 Mar 1.

PMID:
29496663
2.

Identification of novel FLT3 kinase inhibitors.

Pauwels D, Klaassen H, Lahortiga I, Kilonda A, Jacobs K, Sweron B, Corbau R, Chaltin P, Marchand A, Cools J.

Eur J Med Chem. 2013 May;63:713-21. doi: 10.1016/j.ejmech.2013.03.024. Epub 2013 Mar 21.

PMID:
23567961
3.

Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia.

De Keersmaecker K, Atak ZK, Li N, Vicente C, Patchett S, Girardi T, Gianfelici V, Geerdens E, Clappier E, Porcu M, Lahortiga I, LucĂ  R, Yan J, Hulselmans G, Vranckx H, Vandepoel R, Sweron B, Jacobs K, Mentens N, Wlodarska I, Cauwelier B, Cloos J, Soulier J, Uyttebroeck A, Bagni C, Hassan BA, Vandenberghe P, Johnson AW, Aerts S, Cools J.

Nat Genet. 2013 Feb;45(2):186-90. doi: 10.1038/ng.2508. Epub 2012 Dec 23.

4.

The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220.

Pauwels D, Sweron B, Cools J.

Haematologica. 2012 Nov;97(11):1773-4. doi: 10.3324/haematol.2012.069781. Epub 2012 Aug 8. No abstract available.

Supplemental Content

Loading ...
Support Center